The NIH should adopt a more experimental approach to funding, allowing for high-risk, high-reward research that traditional models might overlook.

The future holds the potential to eradicate diseases, with nonprofits working to identify all human druggable targets to aid the drug industry.

I suspect there are many existing drugs that could be reused in significant ways with minor modifications, and we are very close to discovering something great.

Look for startups that pursue ambitious or unconventional ideas; these often attract top talent and can lead to significant innovations.

Partnerships with Eli Lilly and Novartis have allowed us to tackle challenging problems in drug design, leading to the discovery of new chemical matter.

Finding valuable unknown truths is essential for innovators, as it allows them to do things that others can't, leading to unique opportunities.

Investing in things that aren't software is okay if you believe in the founder's expertise; there are many great opportunities in biotech that could lead to significant exits.

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

Companies with particularly novel ideas can consider press outreach even before launching a product, especially in fields like biotechnology.